Lupin Partners with Spektus to Launch Novel Antidepressant DeslaFlex™ in Canada

Lupin Limited has entered into a licence and supply agreement with Spektus Pharma to commercialise the antidepressant DeslaFlex™ in Canada.

DeslaFlex™ is a new antidepressant formulation developed using Spektus’s Flexitab™ oral drug-delivery technology and is designed to support the treatment of Major Depressive Disorder.

Strategic Importance of the Deal

The collaboration combines Lupin’s strong commercial presence in Canada with Spektus’s expertise in developing innovative drug formulations.
This partnership is expected to:

• Expand Lupin’s central nervous system (CNS) treatment portfolio
• Provide new and flexible treatment options for patients with depression
• Create a platform for launching additional speciality medicines in the future

Management Commentary

Lupin’s leadership highlighted that the agreement strengthens its long-term commitment to CNS therapies and to improving healthcare access in Canada.

Spektus’s management described the partnership as a major step toward commercial execution, supported by Lupin’s global brand and established market reach.

About Lupin

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, with products available in more than 100 markets.
The company focuses on branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients across therapy areas such as respiratory, cardiovascular, diabetes, anti-infective, gastrointestinal, CNS, and women’s health.

Read More: RBI to Overhaul Lead Bank Scheme for Enhanced Effectiveness!

Lupin Share Price Movement

Lupin share price (NSE: LUPIN) closed at ₹2,219.40 on February 16, rising ₹20.10 (0.91%) during the day. The stock opened at ₹2,219.30, touched an intraday high of ₹2,238.80, and slipped to a low of ₹2,191.90. Over the past year, the stock has traded between a 52-week high of ₹2,244.50 and a 52-week low of ₹1,795.20, while offering a dividend yield of 0.54% and a quarterly dividend of ₹3.00 per share.

Conclusion

The agreement with Spektus marks an important step in Lupin’s strategy to expand its speciality and CNS portfolio globally. By bringing DeslaFlex™ to Canada, the company aims to improve treatment flexibility for depression while strengthening its long-term growth in international speciality markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.